Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.670 -0.055 (-0.96%)
Official Closing Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,507,887
Open 5.760
Bid (Size) 5.700 (10)
Ask (Size) 5.880 (3)
Prev. Close 5.725
Today's Range 5.565 - 5.760
52wk Range 3.933 - 7.540
Shares Outstanding 51,278,539
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-4.1%
-4.1%
1 Month
-17.9%
-17.9%
3 Month
-5.5%
-5.5%
6 Month
+9.9%
+9.9%
1 Year
+6.4%
+6.4%

More News

Read More
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Posts Q2 Profit on Asset Sale
Via The Motley Fool
Topics Intellectual Property
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
From Abeona Therapeutics Inc.
Via GlobeNewswire
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
From AscellaHealth, LLC
Via GlobeNewswire
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Which stocks have an unusual volume on Thursday?
Via Chartmill
Wednesday's session: top gainers and losers
Via Chartmill
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Via Benzinga

Frequently Asked Questions

Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 5.670
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 09/16/25 04:00 PM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 290.75M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 291M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.